Company News

Avicanna Announces Filing of Annual Financial Statements for Year Ended December 31, 2021

Avicanna Announces Filing of Annual Financial Statements for Year Ended December 31, 2021

$3.3M in revenue representing 108% Y-Y growth, significant growth in finished product sales

Total of 4 brands, 16 SKU's and 35 "cannabis 2.0" listings across medical and retail channels in Canada

Expansion of international footprint with entrance into Avicanna's 14 th international market

Avicanna Inc. ("Avicanna" or the "Company ") (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products, is pleased announce the filing of its annual financial statements for the year ended December 31 st 2021 and provide a corporate update.

Aras Azadian, CEO stated, "2021 was the most progressive and successful year for our team which managed to accomplish numerous remarkable milestones while navigating unprecedented internal and external challenges. We have successfully commercialized and demonstrated the differentiated value of our proprietary products through four brands across both medical and retail channels in Canada and in parallel have established strategic footprints across several international markets."

2021 corporate highlights

  • Total fiscal 2021 revenue of $3.3M representing growth of 108% from fiscal 2020 ($1.57M) . Record quarterly revenue of approximately $1.2M in the fourth quarter of 2021, representing the fourth consecutive quarter-over-quarter increase of approximately 20%, minimum.

  • Revenue growth driven by sales of proprietary cannabinoid-based products sold across global sales channels . This includes 69,000 units sold in the fourth quarter of 2021, representing a 160% growth from the third quarter 2021. A total of 124,000 units was delivered in fiscal 2021 compared to 4,100 units delivered in fiscal 2020.
  • Launched a total of 16 "cannabis 2.0" proprietary product SKUs as of December 31, 2021, in Canada including RHO Phyto, Pura HW, Viola, and re+Play branded products. Expanded distribution channels through a total of 35 "cannabis 2.0" product listings across medical and adult-use channels in Canada, signifying an increase of 37% from the third quarter of 2021.
  • Expanded its partnership with the Medical Cannabis by Shoppers™ online portal with a total of 13 SKUs available to patients and the medical community including all four commercial brands as at December 31, 2021.

  • The launch of re+Play branded CBD topicals across medical and adult use channels in Canada . re+PLAY is a sports performance and recovery-focused brand founded by National Basketball Association ("NBA") veteran Al Harrington with evidence-based CBD formulations developed in partnership with Avicanna.

  • Viola Brands Nationwide launch in Canada through medical channels in partnership with Medical Cannabis by Shoppers and across adult use channels in Ontario, New Brunswick, and Saskatchewan . Avicanna's partnership with Viola brings the US equity-focused brand founded by NBA veteran, Al Harrington, to Canada for the first time.

  • The Company filed a patent on its advanced oral cannabinoid drug delivery system related to neurological disorders including a range of liquids, capsules, powders, and controlled release tablets utilizing proprietary self-emulsifying drug delivery systems (SEDDS) technology. The formulations offer enhanced stability, bioavailability and controlled release of cannabinoids including (CBD, THC, CBG, CBN and THCv) and are intended to be utilized in global medical and pharmaceutical products.

  • IP licensing and distribution partnership with established Argentinian pharmaceutical company. The partnership will focus on the licensing, supply and expected commercialization of the Company's drug candidate Trunerox™ in Argentina in the second half of fiscal 2022.

  • Avicanna's subsidiary obtains Good Agricultural and Collection Practices ("GACP") Certification in Colombia, which will allow the Company's Aureus-branded raw material include low cost and sustainable cannabis biomass and flower for sale and export to the global marketplace.

  • The opening of the Company's 14 th international market across four continents including the initial export and commercialization of its CBD skin care line Pura H&W™ in the United States and its medical cannabis brand RHO Phyto™ into the Caribbean region.

  • International expansion of Aureus branded products including the first commercial export of CBG, a rare cannabinoid, into the European Union and initial export of psychoactive cannabinoids into Chile. Additionally, the Company completed initial exports of its proprietary genetics with completed exports of feminized seeds into Argentina and Peru.

Other highlights subsequent to Q4 2021

  • 2022 strategy and guidance release including the Company's forecasted revenue of $9M from global operations, which is expected to be led by the anticipated sales of approximately 310,000 units of proprietary cannabinoid-based products.
  • Supply Agreement with Chilean Pharmaceutical Pioneer Knop Laboratorios S.A. Expansion of the relationship, originally established in 2020. Supply of Avicanna's active pharmaceutical ingredients for existing commercial and pipeline of pharmaceutical products in South America.
  • Changes to the Board of Directors and executive team with two experienced pharmaceutical executives including the appointment of Eileen McCormack to the Board of Directors and Stephen Kim as the Chief Legal Officer.
  • Strategic Partnership with Tetra Bio-Pharma, which will encompass three potential strategic pillars across supply of API, commercialization of prescription products, and co-development of pharmaceutical drug candidates.
  • Commenced of Epidermolysis Bullosa studies with the Hospital for Sick Children, the study led by Dr. Elena Pope is analyzing the efficacy of the company's dermatological pharmaceutical product on rare skin disease.

The Company is also hosting an update webinar on Tuesday April 5 th in collaboration with CHFIR, if you are interested in attending, please sign up through the provided link. https://tinyurl.com/AVCN050422

About Avicanna Inc.

Avicanna is an innovative, commercial-stage, and international biopharmaceutical company focused on the development, advancement, and commercialization of evidence-based cannabinoid-based products for the global consumer, as well as medical and pharmaceutical market segments. In leading global cannabinoid advancements, the Company actively collaborates with leading Canadian academic and medical institutions. Avicanna has established a scientific platform including R&D and clinical development that has led to the commercialization of more than thirty products across four main market segments:

Medical Cannabis & Wellness Products: Marketed under the RHO Phyto™ brand these medical and wellness products are a line of pharmaceutical-grade cannabinoid products containing varying ratios of cannabidiol ("CBD") and tetrahydrocannabinol ("THC"). The product portfolio contains a full formulary of products including oral, sublingual, topical, and transdermal deliveries that have been designed for controlled dosing, enhanced absorption and stability studies supported by pre-clinical data. The formulary is marketed with consumer, patient and medical-community education and training.

CBD Derma-Cosmetic Products: Marketed under the Pura H&W™ or Pura Earth™ brands, these registered, clinically tested, derma-cosmetic products include a portfolio of functional CBD topical products.

Pharmaceutical Pipeline: Leveraging Avicanna's scientific platform, vertical integration, and real-world evidence, Avicanna has created a pipeline of patent-pending drug candidates that are indication-specific and in various stages of clinical development and commercialization. These cannabinoid-based drug candidates look to address unmet medical needs in the areas of dermatology, chronic pain, and various neurological disorders. Avicanna's first pharmaceutical preparation (Trunerox™) is in the drug registration stage in South America.

Cannabinoid Raw Materials: Marketed under the Aureus™ brand, the Company's raw material business has successfully completed sales to 12 countries. Aureus™ offers cannabis dried flower, standardized seeds, full-spectrum extracts, and cannabinoid distillates, isolated cannabinoids such as CBD, THC, cannabigerol ("CBG") and other rare cannabinoids. Aureus™ products are produced at Santa Marta Golden Hemp S.A.S, the Company's majority-owned subsidiary in Colombia, which is also GACP certified and has United States Department of Agriculture USDA National Organic Program certification for its hemp cultivar.

SOURCE Avicanna Inc.

Stay Connected

For more information about Avicanna, visit www.avicanna.com , contact Ivana Maric by email at info@avicanna.com or Perry Rapagnap at perry@chfir.com or 416-868-1079 x 230.

Follow us on social media on LinkedIn , Twitter , Facebook or Instagram .

The Company posts updates through videos from the official Company YouTube channel https://www.youtube.com/channel/UCFXPBGdKSxOUOf_VZoSFSUA .

Cautionary Note Regarding Forward-Looking Information and Statements

This news release contains "forward-looking information" within the meaning of applicable securities laws. Forward-looking information contained in this news release may be identified by the use of words such as, "may", "would", "could", "will", "likely", "expect", "anticipate", "believe, "intend", "plan", "forecast", "project", "estimate", "outlook" and other similar expressions. Forward-looking information contained in this news release includes, without limitation, statements related to the Offering, the use of the proceeds of the Offering, the receipt of all approvals of the Toronto Stock Exchange in connection with the Offering, statements with respect to the Company's future business operations, the opinions or beliefs of management and future business goals. Although the Company believes that the expectations and assumptions on which such forward looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. Forward-looking information is subject to a variety of risks and uncertainties that could cause actual events or results to differ materially from those projected in the forward-looking information. Such risks and uncertainties include, but are not limited to current and future market conditions, including the market price of the common shares of the Company, and the risk factors set out in the Company's annual information form dated September 3, 2021 and final short form prospectus dated November 27, 2020, filed with the Canadian securities regulators and available under the Company's profile on SEDAR at www.sedar.com. The statements in this news release are made as of the date of this release. The Company disclaims any intent or obligation to update any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.


Primary Logo

News Provided by GlobeNewswire via QuoteMedia

AVCN:CA
Avicanna Announces Extension of Term Loan

Avicanna Announces Extension of Term Loan

Avicanna Inc. (" Avicanna " or the " Company ) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a commercial stage, international biopharmaceutical company focused on the commercialization of evidence-based, cannabinoid based products, announces that it has entered into a extension agreement (the " Extension Agreement ") in connection with its senior secured term loan previously announced on August 19, 2021 (the " Term Loan "). In accordance with the Extension Agreement, the maturity date of the Term Loan was extended by five months, from October 19, 2022 to March 19, 2023 (the " New Maturity Date ").

Pursuant to the Extension Agreement, the Company will continue to make interest payments as required by the original loan agreement in respect of the Term Loan, and will also make monthly repayments of principal beginning in November, 2022 and ending in February, 2023, following which the outstanding principal on the Term Loan will come due on the New Maturity Date. The Term Loan continues to bear interest at 5% per annum, calculated monthly.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Avicanna Files Complete Patent Specifications Relating to a Novel Cannabinoid Formulation for Reducing Incidence of Seizures and Sudden Unexpected Death in Epilepsy

Avicanna Files Complete Patent Specifications Relating to a Novel Cannabinoid Formulation for Reducing Incidence of Seizures and Sudden Unexpected Death in Epilepsy

Avicanna Inc. (" Avicanna " or the " Company ") (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a commercial stage, international biopharmaceutical company focused on the commercialization of evidence-based, cannabinoid-based products, is pleased to announce that it has formalized its provisional patent application, entitled "Methods for Reducing or Eliminating Incidence of Seizures and Sudden Unexpected Death in Epilepsy", for the use of a novel cannabinoid formulation (the "Formulation Candidate") after completion of in-vivo animal studies.

The formal application is filed with WIPO by claiming the priority date of US provisional application filed in September 2022 using the Patent Co-operation Treaty (PCT) system.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Avicanna Introduces a New Medical Cannabis Education Online Portal, "Avicenna Academy" for Health Care Professionals

Avicanna Introduces a New Medical Cannabis Education Online Portal, "Avicenna Academy" for Health Care Professionals

The education portal provides modules, case studies and other resources related to medical cannabis for Health Care Professionals

Established with the support of experts in the fields of pain management, neurology, and dermatology, the portal is designed to address potential gaps in knowledge and training related to the potential use of cannabis in a medical context

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Avicanna Expands its Epilepsy Research Program with a New Collaboration with the University of Toronto

Avicanna Expands its Epilepsy Research Program with a New Collaboration with the University of Toronto

Dr. Mac Burnham's team will explore Avicanna's drug candidate and its proprietary combination of cannabinoids in pre-clinical model for seizures.

Avicanna further expands its current research and commercial focus in Epilepsy which is supported by current medical cannabis sales and on-going research with UHN

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Avicanna Announces Results of Annual General and Special Meeting

Avicanna Announces Results of Annual General and Special Meeting

Avicanna Inc. (" Avicanna " or the " Company ") (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a commercial stage, international biopharmaceutical company focused on the commercialization of evidence-based, cannabinoid-based products, is pleased to announce that all of management's nominees listed in the Company's management information circular dated July 28, 2022 (the " Circular ") were elected as directors of the Company at Avicanna's annual general and special meeting of shareholders held on August 31, 2022 (the " Meeting ").

The detailed results of the vote for the election of directors held at the Meeting are set out below.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
cannabis plants with bitcoin

Cannabis Weekly Round-Up: Software Firm Pivots to Bitcoin Mining

In a surprising move, enterprise software firm Akerna (NASDAQ:KERN), which has developed programs to aid the cannabis industry, will merge with a Bitcoin miner and sell its software business to POSaBIT Systems (CSE:PBIT,OTCQX:POSAF).

Also this week, a Canadian cannabis operator received a warning from a leading exchange for its low trading numbers.

Keep reading to find out more cannabis highlights from the past five days.

Keep reading...Show less

Curaleaf Announces Launch of Adult-Use Cannabis Sales at Stamford, CT Dispensary

Stamford is Curaleaf's first dispensary in Connecticut to serve adult-use consumers

Curaleaf Holdings, Inc. (CSE: CURA) (OTCQX: CURLF) ("Curaleaf" or the "Company"), a leading international provider of consumer cannabis products, today announced that it has been approved by the Connecticut Department of Consumer Protection to commence adult-use sales at its Stamford, Connecticut location, beginning Saturday, January 28 at 10:00 a.m. Curaleaf Stamford, located at 814 East Main St, is the Company's first dispensary in the state to open its doors to adult-use customers.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Trulieve Opening Medical Marijuana Dispensary in Winter Haven, FL

New dispensary expands patient access to medical cannabis; grand opening specials available

Trulieve Cannabis Corp. (CSE: TRUL )(OTCQX: TCNNF ) ("Trulieve" or "the Company"), a leading and top-performing cannabis company in the United States today announced the opening of a new medical dispensary in Winter Haven, Florida . Located at 6000 Cypress Gardens Blvd., the doors will open at 9 a.m. on Saturday, January 28 with ongoing regular hours of 9 a.m. 9 p.m. from Monday through Saturday and 10 a.m. 8 p.m. on Sunday .

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Curaleaf Announces Closure of Operations in California, Colorado and Oregon

Proactive Exit Will Generate Additional Cash and Improve Margins in Non-SAFE Banking Environment

2023 Free Cash Flow Expected to Exceed $125 Million

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Aurora Cannabis to Host Second Quarter Fiscal Year 2023 Investor Conference Call

Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ: ACB) (TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, announced today that it has scheduled a conference call to discuss the results for its second quarter fiscal year 2023 on Thursday, February 9, 2023 at 5:00 p.m. Eastern Time | 3:00 p.m. Mountain Time . The Company will report its financial results for the second quarter fiscal year 2023 after the close of markets that same day.

Aurora Cannabis Logo (CNW Group/Aurora Cannabis Inc.)

Conference Call Details

DATE: Thursday, February 9, 2023
TIME: 5:00 p.m. Eastern Time | 3:00 p.m. Mountain Time
WEBCAST: Click here

Miguel Martin , Chief Executive Officer, and Glen Ibbott , Chief Financial Officer, will host the conference call and question and answer period. This weblink has also been posted to the Company's "Investor Info" link at https://investor.auroramj.com/ under "News & Events".

About Aurora

Aurora is a global leader in the cannabis industry, serving both the medical and consumer markets. Headquartered in Edmonton, Alberta , Aurora is a pioneer in global cannabis, dedicated to helping people improve their lives. The Company's adult-use brand portfolio includes Aurora Drift , San Rafael '71 , Daily Special , Whistler , Being and Greybeard , as well as CBD brands, Reliva and KG7 . Medical cannabis brands include MedReleaf, CanniMed, Aurora and Whistler Medical Marijuana Co. Aurora also has a controlling interest in Bevo Farms , North America's leading supplier of propagated agricultural plants. Driven by science and innovation, and with a focus on high-quality cannabis products, Aurora's brands continue to break through as industry leaders in the medical, performance, wellness and adult recreational markets wherever they are launched. Learn more at www.auroramj.com and follow us on Twitter and LinkedIn .

Aurora's common shares trade on the NASDAQ and TSX under the symbol "ACB".

Forward Looking Statements

This news release includes statements containing certain "forward-looking information" within the meaning of applicable securities law ("forward-looking statements"). Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements made in this news release include statements regarding timing of the release of the Company's financial statements for second quarter ended December 31, 2022 and scheduling of the conference call to discuss results.

These forward-looking statements are only predictions. Forward looking information or statements contained in this news release have been developed based on assumptions management considers to be reasonable. Material factors or assumptions involved in developing forward-looking statements include, without limitation, publicly available information from governmental sources as well as from market research and industry analysis and on assumptions based on data and knowledge of this industry which the Company believes to be reasonable. Forward-looking statements are subject to a variety of risks, uncertainties and other factors that management believes to be relevant and reasonable in the circumstances could cause actual events, results, level of activity, performance, prospects, opportunities or achievements to differ materially from those projected in the forward-looking statements. These risks include, but are not limited to, the ability to retain key personnel, the ability to continue investing in infrastructure to support growth, the ability to obtain financing on acceptable terms, the continued quality of our products, customer experience and retention, the development of third party government and non-government consumer sales channels, management's estimates of consumer demand in Canada and in jurisdictions where the Company exports, expectations of future results and expenses, the risk of successful integration of acquired business and operations, management's estimation that SG&A will grow only in proportion of revenue growth, the ability to expand and maintain distribution capabilities, the impact of competition, the general impact of financial market conditions, the yield from cannabis growing operations, product demand, changes in prices of required commodities, competition, and the possibility for changes in laws, rules, and regulations in the industry, epidemics, pandemics or other public health crises, including the current outbreak of COVID-19, and other risks, uncertainties and factors set out under the heading "Risk Factors" in the Company's annual information form dated September 20, 2022 (the "AIF") and filed with Canadian securities regulators available on the Company's issuer profile on SEDAR at www.sedar.com and filed with and available on the SEC's website at www.sec.gov . The Company cautions that the list of risks, uncertainties and other factors described in the AIF is not exhaustive and other factors could also adversely affect its results. Readers are urged to consider the risks, uncertainties and assumptions carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such information. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.

Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/aurora-cannabis-to-host-second-quarter-fiscal-year-2023-investor-conference-call-301730523.html

SOURCE Aurora Cannabis Inc.

Cision View original content to download multimedia: http://www.newswire.ca/en/releases/archive/January2023/26/c1397.html

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Cresco Labs Welcomes Patients to 22nd Sunnyside Dispensary in Florida

Cresco Labs (CSE:CL) (OTCQX:CRLBF) ("Cresco" or "the Company), a vertically integrated multistate cannabis operator and the No. 1 U.S. wholesaler of branded products, today announced the opening of a new Sunnyside dispensary in Lutz, Florida. Sunnyside Lutz joins its sister locations in Tampa, Clearwater and St. Petersburgh in serving patients residing around the Tampa Bay area. The new store is Cresco Labs' 22 nd dispensary in Florida and 56 th dispensary nationwide.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230125005221/en/

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×